Popular on Amzeal
- Waev and GEM vehicles Join PalMar Studios as a Primary Partner on "Triangle Park," a Documentary on the NFL's First-Ever Game
- The People Below - A Short Film Set in Ethiopia
- Onlive Server Brings Malaysia VPS Server with Unlimited Size Anti-DDoS Protection
- OpenEMR Achieves ONC 2015 Cures Update Certification with Groundbreaking Release 7.0
- ESL Model 4511 5 to 1 Switch for Connection to Multiple USB Devices with No Enclosure
- The 12th Annual Igniting Souls Conference
- BECU Data Breach Exposes Confidential Information: Murphy Law Firm Investigates Legal Claims
- Escape to the Sea Island Writers Retreat and Hone Your Writing
- Ellipse Solutions Receives Best Places to Work Award
- Diedra Harrison-Greenaway launches new book titled: The Blueprint: A Guide Towards Cannabis Business Ownership
Similar on Amzeal
- Update on I-5 Project, Black Prime Contractor Raimore Construction
- Ironside Human Resources Ranks No.765 on the 2022 Inc. 5000 Annual List
- Global Workplace Mental Health Provider CuraLinc Healthcare Debuts on the Inc. 5000 List
- Arizona Fireplaces Ranks No. 3277 on the 2022 Inc. 5000 Annual List
- Loxperts Inc. launches the first-ever on-demand freelancer marketplace dedicated to localization experts
- Hoy to Keep Your Life Productive by Ismail Sirdah
- Regent Surgical Health and Ascension Texas Joint Venture on The Orthopedic Surgery Center of Central Texas
- Arizona Pest Control To Support Local High School Sports And Education Programs
- Positive Powerful Women Gather to Promote Unity in the Grand Canyon State
- Unprecedented Stress Levels Reveal Productivity Loss in the Billions; ASCEND Method Enters the Market
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Amzeal News/10488483
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2022, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 37,250 shares of Puma common stock to six new non-executive employees.
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, August 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on Amzeal News
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, August 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on Amzeal News
- ThrottleNet Named #1 Cybersecurity Firm In St. Louis By Small Business Monthly
- Aquia Inc. Announces Government and Cyber Veteran Advisory Board; Names Renee Wynn Inaugural Member
- Ironside Human Resources Ranks No.765 on the 2022 Inc. 5000 Annual List
- Robotic-Assisted Dental Implant System Gets Rave Reviews from Patients
- CareWell Health Medical Center Expands Leadership Team, Adds New COO
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Filed Under: Business
0 Comments
Latest on Amzeal News
- 74% of marketing funnels do not make money - New study by Growth Thinking
- ES Labs Pathway Model 4126 DB9 Automatic Fallback A/B Switcher with RS232 Remote
- Bold New Book, If Only We Knew, Offers A Framework To Understand And Solve Today's Social Issues
- Living Waters Inc to Host the "2022 Mental Health Summit"
- Historical Lectures and More at Morven this September
- Wood Underwear® FW22 Introduces New Styles in Lounge
- Loxperts Inc. launches the first-ever on-demand freelancer marketplace dedicated to localization experts
- AI-designed camera only records objects of interest while being blind to others
- Wayne Moulton Named Vice President ANZ at Hoppr
- Can Picking Up the Phone Save Lives & Provide Long COVID Cures? UCSF & Partners' Study To Find Out
- Reliable Parts is Named a Finalist in 2022 SuperNova Awards by Constellation Research
- Agent Timothy Braue Awarded Prestigious "Premier Luxury Marketing Consultant" Certification
- Why should I use a company for Air Duct Cleaning in NJ
- Let's Finally Meet The Man That Fronts The Grammy Nominated Artist "Special Request Ft Rey T."
- Federal Defendants Acquitted of Conspiracy to Possess and Possession of 279 Kilos of Cocaine
- NICE DCV and EnginFrame: Latest Updates Announced by Nor-Tech
- ITsavvy Wins IT Vendor of the Year Award
- Radar-Based Vital Sign Sensor Saves the Life of At-Risk Inmate
- Hoy to Keep Your Life Productive by Ismail Sirdah
- How to Choose the Best Bamboo Cheese Board for Your Kitchen